Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core protein
Dmytro Kornyeyev,Zhijuan Song,Stacey Eng,Cameron Soulette,Ricardo Ramirez,Jennifer Tang,Qin Yue,Raju Subramanian,Shiva Zaboli,Christina Moon,Jane Tam,Jens Brodbeck,Abhishek Aggarwal,Lauri Diehl,Simon P Fletcher,Anastasia Hyrina,Meghan M Holdorf,Dara Burdette,Simon P. Fletcher,Meghan M. Holdorf
DOI: https://doi.org/10.1128/aac.00420-24
IF: 5.938
2024-05-24
Antimicrobial Agents and Chemotherapy
Abstract:ABSTRACT Capsid assembly mediated by hepatitis B virus (HBV) core protein (HBc) is an essential part of the HBV replication cycle, which is the target for different classes of capsid assembly modulators (CAMs). While both CAM-A (“aberrant”) and CAM-E (“empty”) disrupt nucleocapsid assembly and reduce extracellular HBV DNA, CAM-As can also reduce extracellular HBV surface antigen (HBsAg) by triggering apoptosis of HBV-infected cells in preclinical mouse models. However, there have not been substantial HBsAg declines in chronic hepatitis B (CHB) patients treated with CAM-As to date. To investigate this disconnect, we characterized the antiviral activity of tool CAM compounds in HBV-infected primary human hepatocytes (PHHs), as well as in HBV-infected human liver chimeric mice and mice transduced with adeno-associated virus-HBV. Mechanistic studies in HBV-infected PHH revealed that CAM-A, but not CAM-E, induced a dose-dependent aggregation of HBc in the nucleus which is negatively regulated by the ubiquitin-binding protein p62. We confirmed that CAM-A, but not CAM-E, induced HBc-positive cell death in both mouse models via induction of apoptotic and inflammatory pathways and demonstrated that the degree of HBV-positive cell loss was positively correlated with intrahepatic HBc levels. Importantly, we determined that there is a significantly lower level of HBc per hepatocyte in CHB patient liver biopsies than in either of the HBV mouse models. Taken together, these data confirm that CAM-As have a unique secondary mechanism with the potential to kill HBc-positive hepatocytes. However, this secondary mechanism appears to require higher intrahepatic HBc levels than is typically observed in CHB patients, thereby limiting the therapeutic potential.
pharmacology & pharmacy,microbiology